0001626971 false 0001626971 2023-03-29 2023-03-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 29, 2023

 

 

 

CORVUS PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 
         
Delaware   001-37719   46-4670809

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification Number)

 

863 Mitten Road, Suite 102

Burlingame, CA 94010

(Address of principal executive offices, including Zip Code)

 

Registrant’s telephone number, including area code: (650) 900-4520

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: 

 

Title of each class Trading symbol(s) Name of each exchange on which registered
Common Stock, Par Value $0.0001 per share CRVS Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On March 29, 2023, the Compensation Committee (the “Committee”) of the Board of Directors of Corvus Pharmaceuticals, Inc.’ (the “Company”) approved a reduction in the base salary of Dr. Richard Miller, the Company’s President and Chief Executive Officer, from $300,000 per year to $34,840, effective as of March 31, 2023. In connection with the reduction in Dr. Miller’s base salary, the Committee also approved the grant of an option to Dr. Miller to purchase 800,000 shares of Corvus’ common stock, with such option being granted on March 31, 2023 and vesting monthly over 36 months.

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CORVUS PHARMACEUTICALS, INC.
   
Date: April 3, 2023

By: /s/ Leiv Lea

Leiv Lea

Chief Financial Officer

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Dec 2024 to Jan 2025 Click Here for more Corvus Pharmaceuticals Charts.
Corvus Pharmaceuticals (NASDAQ:CRVS)
Historical Stock Chart
From Jan 2024 to Jan 2025 Click Here for more Corvus Pharmaceuticals Charts.